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 BACKGROUND 
 Buerger’s disease or Thromboangiitis obliterans is a type 
of vasculitis in young, mostly male subjects- remains 
strangely linked to smoking, which determines its ocur-
rence, progression and prognosis by yet unknown 
mechanisms. 1 Sometimes it presents with multisystemic 
complaints. 
 The diagnosis and treatment of this entity is challenging, 
since it requires the exclusion of many other causes and a 
multidisciplinary approach. An illustrative case-report and 
literature review is presented. 
 CASE PRESENTATION 
 A 34-year-old black male presented in the medicine clin-
ics with a 6 year history of ulcers in the ﬁ ngertips of both 
hands and feet with progressive worsening: acrocyano-
sis, slow healing, necrosis and ﬁ nally loss of substance. 
Raynaud’s phenomenon was absent. Sympaticectomy was 
unsuccessfully tried. He also referred recurrent episodes of 
‘migratory thrombophlebitis’, preferentially involving the 
legs bilaterally and left forearm. A biopsy made in the past 
was consistent with local thrombophlebitis. 
 The patient had a known history of smoking (20 pack-
year), controlled asthma, sinusitis and primary syphilis 
(1995). No other vascular risk factor was detected, namely 
diabetes, dyslipidemia or drug abuse. 
 On clinical examination, the patient presented a cyan-
otic ulcerated lesion involving the two distal thirds of 
the second left toe ( ﬁ gure 1 ). The patient had an ulcer-
ated lesion on the ﬁ rst right toe with purulent discharge. 
Healed lesions with loss of substance in the ﬁ rst left toe 
and second and fourth ﬁ ngers of right hand were present 
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 Summary 
 Buerger’s disease or Thromboangiitis obliterans is a segmental infl ammatory disease that affects the vessels and nerves of the extremities. It 
usually affects men below 45 years old and correlates with tobacco, as a predisposing factor. The authors present the case of a 34-year-old 
male, with ulcers in the fi ngertips with progressive worsening: acrocyanosis, slow healing, necrosis and fi nally loss of substance. Dorsalis 
pedis and posterior tibial pulses were not palpable. Personal history of heavy smoking was (20 pack-years). The angiography revealed 
proximal occlusion of the left posterior tibial and interosseal arteries, with distal circulation by the anterior tibial artery. He was submitted to 
disarticulation of the second left toe and therapy with pentoxifyline and iloprost infusion, calcium antagonist, antiplatelet drugs, statin and low 
molecular weight heparin (later replaced by oral anticoagulation). Improvement was seen of active vascular lesions and pain symptoms. 
 Figure 1  Ulcerated and cyanotic lesion of the second left toe. 
 Figure 2  Scar lesions with substance loss of the second and 
fourth right fi ngers. 
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( ﬁ gures 2 and  3 ). Dorsalis pedis and posterior tibial pulses 
were absent. 
 The differential diagnoses were: systemic embolisation 
or thrombophilia, Buerger’s disease, vasculitis of large and 
medium-sized vessels, atherosclerotic arteriopathy (less 
likely in this age group) and systemic lupus erythemato-
sus- related vasculitis. 
 The study for thrombophilia and immunology was nega-
tive ( table 1 ). A possible source of systemic embolism was 
excluded by transthoracic echocardiogram and carotid-
vertebral Doppler. The viral (HIV, hepatitis B virus and 
hepatitis C virus) and syphilitic serologies were negative. 
The thoracoabdominopelvic CT was unremarkable. The 
nailfold capillaroscopy was suggestive of systemic vascular 
disease, with active capillaritis. The angiography (abdomi-
nal, upper and lower limbs) revealed proximal occlusion of 
the left posterior tibial and interosseal arteries, with distal 
circulation by the anterior tibial artery ( ﬁ gure 4 ). A vascular 
surgery consult excluded the need for a revascularisation 
procedure (endovascular /surgery). 
 Disarticulation of the second left toe was performed 
along with medical therapy with pentoxifylline and ilo-
prost infusion, calcium antagonist (nifedipine), antiplatelet 
drug (aspirin), statin (atorvastatin), corticosteroid (pred-
nisolone), low molecular weight heparin (later replaced 
by oral anticoagulation) and analgesic therapy (morphine, 
amitriptyline, gabapentin, paracetamol and ibuprofen). 
 OUTCOME AND FOLLOW-UP 
 The combination therapy: anticoagulation strategy, aspi-
rin, prednisolone, pentoxifylline, nifedipine and atorvas-
tatin revealed a long-term efﬁ cacy. Adherence to tobacco 
withdrawal was also crucial. 
 DISCUSSION 
 Buerger’s disease or Tromboangiitis obliterans (TAO) is a 
non-atherosclerotic segmental inﬂ ammatory disease that 
most commonly affects the small and medium-sized arter-
ies, veins and nerves of the arms and legs. 2 
 It is most common in the Orient, Southeast Asia, India 
and the Middle East. 3 In fact, all racial and ethnic groups 
appear to be susceptible. The recent decline in the inci-
dence of TAO has been more apparent than real and has 
most likely been related to initial over-diagnosis of the dis-
ease (based on recognition of its status as a distinct entity), 
followed by underdiagnosis (based on scepticism concern-
ing its status). Patients with TAO constitute only 4% to 
 Table 1  Relevant laboratory parameters. 
Parameter Value
Haemoglobin 15, 9 (13, 5–18 g/dl
Leucocytes/neutrophils 13300 (4–10) mm 3 ; 60, 7% (37–72)
C reactive protein 2, 7 (<1) mg/dl
ESR 22 (1–20) mm/1st h
Antithrombin III 96% (80–120)
Protein C 101% (70–140)
Protein S 111, 5% (64–129)
Factor V Leiden Negative
Homocysteine 7, 61 (<15) µmol/l
Lupus anticoagulant Negative: 1, 16 (0, 8–1, 2) R
Anticardiolipin IgM-6 (<7) MPL; IgG-10 (<10) GPL
ANA Negative (<1/160)
DNA ds Negative (<1/10)
A-SSA 0.1 (<40) U/ml
A-SSB 0, 1 (<40) U/ml
A-SM/RNP 0, 1 (<40) U/ml
A-SM 0, 1 (<40) U/ml
A-Centromere 0, 1 (<40) U/ml
A-SCL70 0, 1 (<40) U/ml
ANCA-C 0, 1 (<25) U/ml
ANCA-P 0, 1 (<25) U/ml
C3 161 (75–140) mg/dl
C4 38, 8 (10–34) mg/dl
C1q 13, 24 (8–15) mg/dl
Circulating immunocomplexes 1, 6 (<10, 8) µg/dl
 ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibodies; 
A-SCL, antiscleroderma; A-SSA, anti Sjögren’s syndrome A; A-SSB, 
anti Sjögren’s syndrome B; ESR, erythrocyte sedimentation rate; MPL, 
IgM phospholipid units; GPL, IgG phospholipid units; SM/RNP, Smith/
Ribonucleoprotein. 
 Figure 3  Scar lesions with substance loss of the second and 
fourth right fi ngers and fi rst left toe. 
 Figure 4  The angiography (abdominal, upper and lower limbs) 
revealed proximal occlusion of the left posterior tibial and 
interosseal arteries, with distal circulation by the anterior tibial 
artery. 
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5% of all those with ischemic peripheral vascular disease. 4 
More recently, prevalence has been estimated at 12, 6–20 
cases per 100000 people in the United States. 5 
 One hundred years after the original description by Leo 
Buerger, the aetiology of the disease remains unknown. 6 
However, use of or exposure to tobacco is central to the 
initiation and progression of the disease. 2 
 TAO is more common in males (male-to-female ratio, 
3:1); its incidence is believed to be increasing among women, 
and this trend is postulated to be due to the increased prev-
alence of smoking among women. 5 It has been postulated 
that TAO is an ‘autoimmune’ reaction triggered by some 
constituents of tobacco. 7 Patients with the disease show 
hypersensitivity to intradermally injected tobacco extracts, 
have increased cellular sensitivity to types I and III colla-
gen, elevated serum antiendothelial cell antibody titres and 
impaired peripheral vasculature endothelium-dependent 
vasorelaxation. Increased prevalence of HLA-A9, HLA-A54 
and HLA-B5 is observed in these patients, which suggests 
a genetic predisposition to the disease. 5 
 The hypothesis that infectious microorganisms as a 
contribute to the pathophysiology of the disease was also 
studied. 6 An increased prevalence of hepatitis B infection 
was recognised. 6 A recent study examined a possible asso-
ciation with long-term infection of the gums. 8  9 
 Less than 5% of TAO patients are non-smokers. These 
cases might be triggered by cold, frostbite, traumatism of 
extremities or even abuse of sympathicomimetic drugs. 1 
The use of drugs such as cocaine, cannabis and ampheta-
mines may mimic TAO, showing a similar arteriographic 
pattern. 10  11 
 The clinical criteria for TAO, edited by Olin in 2000 
include: age under 45 years; current or recent history of 
tobacco use; presence of distal extremity ischemia, indi-
cated by claudication, pain at rest, ischemic ulcers or gan-
grenes and documented by non-invasive vascular testing; 
exclusion of autoimmune diseases, hypercoagulable states 
and diabetes mellitus; exclusion of a proximal source of 
emboli by echocardiography or arteriography; consistent 
arteriographic ﬁ ndings in the clinically involved and non-
involved limbs. 12 
 Superﬁ cial thrombophlebitis and Raynaud’s phenome-
non occurs in approximately 40% of patients with TAO. 12 
Migrating phlebitis (phlebitis saltans) in young patients is 
therefore highly suggestive of TAO and may parallel dis-
ease activity. 1  2 
 TAO may begin with joint manifestations such as recur-
rent episodes of arthritis of large joints, with transient, 
migratory single-joint episodes accompanied by local signs 
of inﬂ ammation. The wrists and knees are the most fre-
quently involved joints. The arthritis is non-erosive. Joint 
problems precede the diagnosis of TAO by about 10 years 
on average. 1 
 TAO usually begins with ischemia of the distal small arter-
ies and veins. As the disease progresses, it may involve more 
proximal arteries. Large arteries involvement is unusual and 
rarely occurs in the absence of small-vessel occlusive dis-
ease. 2 However, it has been reported in many other vascu-
lar beds. There are case reports of cerebral, coronary, renal, 
mesenteric, pulmonary, iliac and aorta arteries involvement; 
even multiple-organ involvement may exist. 2  12 
 Biopsy and tissue sample are rarely required to estab-
lish the diagnosis. However, in a few cases with unusual 
location, the diagnosis should be established only when 
histopathological examination identiﬁ es the acute-phase 
lesion. 2  3 In all stages, the normal architecture of the ves-
sels wall including the internal elastic lamina remains 
intact and these ﬁ ndings distinguish from atherosclerosis 
and other systemic vasculitis. 3 The most frequent injury is 
the presence of typical giant cell granuloma at the periph-
ery of the thrombus. 6 
 Extensive arterial occlusion accompanied by the devel-
opment of corkscrew collateral vessels is characteristic 
angiographic ﬁ nding, but not pathognomonic. The disease 
is most often conﬁ ned to the distal circulation and is almost 
always infra-popliteal in the lower extremities and distal to 
the brachial artery in the upper extremities. 3 
 Currently, there is no speciﬁ c treatment for TAO. 13 
Absolute discontinuation of tobacco use is the only strat-
egy proven to prevent the progression of Buerger’s disease. 
Smoking as few as 1 or 2 cigarettes daily, using chewing 
tobacco, or even using nicotine replacements may main-
tain the disease activity. 5 Selective cannabinoid receptor 
antagonists, such as rimonabant, which shows promise 
as a treatment for helping patients to stop smoking, open 
up interesting new perspectives for this disease strongly 
related to tobacco use. 1 
 Local hygiene, as well as the treatment of fungal and 
bacterial infection in the extremity, should not be ignored. 4 
Calcium inhibitors are frequently recommended, although 
there is no proof that they are actually effective. Similarly, 
there is no clinical evidence of beneﬁ ts with the use of 
vasodilators, thrombolytic agents, anticoagulants and cor-
ticosteroids. 1  4 Non-steroidal anti-inﬂ ammatory drugs are 
the treatment of choice for superﬁ cial thrombosis. 1 
 Prostaglandins, in particular the intravenous iloprost, 
represents one of the more valid treatments in the TAO. 13 
It has been shown to be effective in improving symptoms, 
accelerating resolution of distal extremity trophic changes, 
and reducing the amputation rate. 5 
 Recent studies have suggested that vascular damage 
caused by endothelin-1 may trigger peripheral arterial 
occlusive disease. The anti-inﬂ ammatory, antiﬁ brotic and 
selective vasodilatory properties of bosentan (endothelin-1 
receptor antagonist) have been shown to alleviate pain at 
rest and reduce the size of ischaemic ulcers caused by dam-
age to the microcirculation. 14 
 Amputation of a limb or a segment of a limb must be 
postponed until after the patient has ceased smoking and 
gangrene has set in with clear demarcation. There is no 
medical evidence that cervical or lumbar sympathectomy 
will improve survival or decrease the amputation rate; nev-
ertheless, by improving collateral circulation and increasing 
superﬁ cial blood ﬂ ow to the skin, such a procedure may 
help heal the ischemic ulceration and thus be beneﬁ cial in 
selected cases. Bypass grafting has been successful in cases 
involving a femoro-popliteal segment. 4 
 A promising new approach is on the edge with the 
use of gene transfer to induce therapeutic angiogenesis 
in TAO. 1 The implantation of autologous bone marrow 
mononuclear cells or mesenchymal stem cells derived 
from human umbilical cord blood into ischemic limbs can 
restore limb function by increasing new collateral vessel 
formation. 15 – 17 
 The clinical course of TAO is characterised by acute 
exacerbations separated by phases of remission that may 
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last several years. 1 A striking dichotomy is observed with 
regard to the prognosis, which is dependent upon whether 
absolute avoidance of tobacco is achieved: 94% avoid 
amputation; 43% may suffer an amputation if they con-
tinue to smoke. 5 
 Learning points 
 ▶  Buerger’s disease or Tromboangiitis obliterans often 
poses a diagnosis challenge and requires a high degree 
of suspicion. 
 It remains a poorly investigated disease. The  ▶
importance of tobacco is consensual and its 
withdrawal is the cornerstone of therapy. 
 The emergence of new vasodilators biological agents  ▶
and gene-or cell-based therapy may provide signifi cant 
tools for the management of this systemic vasculitis. 
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